Antiamyloid therapy for Alzheimer's disease--are we on the right road?
From Reta Lila Weston Laboratories and the Department of Molecular Neuroscience, University College London, London (E.K., J.H.), and Alzheimer's Research UK, Cambridge (E.K.) - both in the United Kingdom.
Eric
E
Karran
John
J
Hardy
D000544:Alzheimer Disease / Q000188:drug therapy*; D016229:Amyloid beta-Peptides / Q000037:antagonists & inhibitors*; D061067:Antibodies, Monoclonal, Humanized / Q000627:therapeutic use*; D005260:Female; D006801:Humans; D008297:Male
D016229:Amyloid beta-Peptides; D061067:Antibodies, Monoclonal, Humanized; C550616:solanezumab; C545458:bapineuzumab